BCL2L1 and breast cancer: In contrast, Bcl-xL and Mcl-1 are widely expressed in ER+ breast cancers, as well as in HER2-amplified and triple negative breast cancers (TNBC) [7], both in pre-malignant lesions [9] and in high grade tumors [8].